Rituximab biosimilar Ruxience approved in the EU

Data show that Ruxience has comparable quality, safety and efficacy to MabThera (rituximab), including results from the REFLECTIONS clinical comparative study in CD-20-positive follicular lymphoma. It has been approved for all of the current indications of MabThera.

Source:

Biospace Inc.